Mutant adeno-associated virus virions and methods of use thereof
The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
1. A recombinant adeno-associated virus (rAAV) virion comprising:
a) a variant AAV capsid protein, wherein the variant capsid protein comprises an amino acid sequence having at least about 95% amino acid sequence identity to the entire length of the amino acid sequence set forth in SEQ ID NO:5, wherein the variant capsid protein confers increased infectivity of a stem cell compared to the infectivity of the stem cell by an AAV virion comprising a wild-type AAV capsid protein, and wherein the variant capsid protein comprises an R459G amino acid substitution; and
b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.
2. The rAAV virion of claim 1 , wherein the rAAV virion exhibits at least 5-fold increased infectivity of a stem cell compared to the infectivity of the stem cell by an AAV virion comprising the wild-type AAV capsid protein.
3. The rAAV virion of claim 1 , wherein the rAAV virion exhibits at least 10-fold increased infectivity of a stem cell compared to the infectivity of the stem cell by an AAV virion comprising the wild-type AAV capsid protein.
4. The rAAV virion of claim 1 , wherein the rAAV virion exhibits at least 25-fold increased infectivity of a stem cell compared to the infectivity of the stem cell by an AAV virion comprising the wild-type AAV capsid protein.
5. The rAAV virion of claim 1 , wherein the rAAV virion exhibits at least 50-fold increased infectivity of a stem cell compared to the infectivity of the stem cell by an AAV virion comprising the wild-type AAV capsid protein.
6. The rAAV virion of claim 1 , wherein the variant capsid protein comprises from one to 15 amino acid sequence substitutions compared to the amino acid sequence of an AAV2 capsid protein set forth in SEQ ID NO:5.
7. The rAAV virion of claim 1 , wherein gene product is an interfering RNA.
8. The rAAV virion of claim 1 , wherein the gene product is a polypeptide.
9. A method of delivering a gene product to a stem cell in an individual, the method comprising administering to the individual a recombinant adeno-associated virus (rAAV) virion according to claim 1 .
10. The method of claim 9 , wherein the gene product is a protein.
11. The method of claim 9 , wherein the gene product is a short interfering RNA.
12. The method of claim 10 , wherein the protein is a growth factor, a morphogen, a cytokine, a receptor, a protein involved in intracellular signal transduction, or a transcription factor.
13. The rAAV virion of claim 1 , wherein the variant capsid protein comprises an amino acid sequence having at least about 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:5.
14. The rAAV virion of claim 1 , wherein the variant capsid protein comprises an amino acid sequence having at least about 99% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:5.
15. A recombinant adeno-associated virus (rAAV) virion comprising:
a) a variant AAV capsid protein, wherein the variant capsid protein comprises:
(i) an amino acid sequence having at least about 95% amino acid sequence identity to the entire length of the amino acid sequence set forth in SEQ ID NO:54, wherein the variant capsid protein comprises V708I and P250S amino acid substitutions relative to SEQ ID NO:5; or
(ii) an amino acid sequence having at least about 95% amino acid sequence identity to the entire length of the amino acid sequence set forth in SEQ ID NO:59, wherein the variant capsid protein comprises S85G and R459G amino acid substitutions relative to SEQ ID NO:5;
wherein the variant capsid protein confers increased infectivity of a stem cell compared to the infectivity of the stem cell by an AAV virion comprising a wild-type AAV capsid protein; and
b) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene product.
16. The rAAV virion of claim 15 , wherein the rAAV virion exhibits at least 5-fold increased infectivity of a stem cell compared to the infectivity of the stem cell by an AAV virion comprising the wild-type AAV capsid protein.
17. The rAAV virion of claim 15 , wherein the rAAV virion exhibits at least 10-fold increased infectivity of a stem cell compared to the infectivity of the stem cell by an AAV virion comprising the wild-type AAV capsid protein.
18. The rAAV virion of claim 15 , wherein the rAAV virion exhibits at least 25-fold increased infectivity of a stem cell compared to the infectivity of the stem cell by an AAV virion comprising the wild-type AAV capsid protein.
19. The rAAV virion of claim 15 , wherein the rAAV virion exhibits at least 50-fold increased infectivity of a stem cell compared to the infectivity of the stem cell by an AAV virion comprising the wild-type AAV capsid protein.
20. The rAAV virion of claim 15 , wherein the variant capsid protein comprises from 5 to 10 or from 10 to 15 amino acid sequence substitutions compared to the amino acid sequence of an AAV2 capsid protein set forth in SEQ ID NO:5.
21. The rAAV virion of claim 15 , wherein gene product is an interfering RNA.
22. The rAAV virion of claim 15 , wherein the gene product is a polypeptide.
23. The rAAV virion of claim 15 , wherein:
the variant capsid protein of (i) comprises an amino acid sequence having at least about 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:54; or
the variant capsid protein of (ii) comprises an amino acid sequence having at least about 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:59.
24. The rAAV virion of claim 15 , wherein:
the variant capsid protein of (i) comprises an amino acid sequence having at least about 99% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:54; or
the variant capsid protein of (ii) comprises an amino acid sequence having at least about 99% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:59.
25. A method of delivering a gene product to a stem cell in an individual, the method comprising administering to the individual a recombinant adeno-associated virus (rAAV) virion according to claim 15 .
26. The method of claim 25 , wherein the gene product is a protein.
27. The method of claim 25 , wherein the gene product is a short interfering RNA.
28. The method of claim 25 , wherein the protein is a growth factor, a morphogen, a cytokine, a receptor, a protein involved in intracellular signal transduction, or a transcription factor.